Stéphane Bancel, Moderna CEO (AP Photo/Markus Schreiber)

Up­dat­ed: Mod­er­na: Not enough flu cas­es in PhI­II tri­al yet to tell ef­fi­ca­cy

One of Mod­er­na’s Phase III stud­ies for its in­fluen­za vac­cine can­di­date for adults, dubbed mR­NA-1010, did not have enough cas­es at the time of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA